Stock & Company Details
Immunovant Inc $IMVT
Price:
N/A
N/A
207M
$6.3B
52 Week High:
N/A
10 Day Average Volume:
N/A
-10.77
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
IMVT technical indicators
Latest Immunovant Inc (IMVT) indicator readings as of 2026-10-09.
IMVT's 14-day RSI is 20.5, in oversold territory. At $30.47 it is trading 4.4% below its 200-day moving average of $31.86, and below its 50-day average of $38.40. Price sits near the lower Bollinger Band ($29.87 to $38.91). ADX reads 29.0, indicating a trending market.
IMVT backtested strategy results
How 4 rule-based strategies performed on Immunovant Inc (IMVT) over recent history, last backtested 2026-09-03. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | -89.9% | 7% | 15 | -94.3% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +249.2% | 30% | 23 | -33.0% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +155.8% | 36% | 28 | -46.6% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | -32.1% | 50% | 32 | -75.1% |
Overview
mmunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Finance Bot
Ask your questions
Start by typing a question below.
